勘误：病例报告：ROS1融合阳性晚期肺腺癌患者对免疫化疗的持久反应：一例病例报告。
Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.
作者信息
Yan Ningning, Huang Siyuan, Li Linlin, Guo Qianqian, Geng Di, Zhang Huixian, Guo Sanxing, Li Xingya
机构信息
Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
出版信息
Front Pharmacol. 2023 Jul 26;14:1256801. doi: 10.3389/fphar.2023.1256801. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.898623.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2022.898623。]
相似文献
1
Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.勘误：病例报告：ROS1融合阳性晚期肺腺癌患者对免疫化疗的持久反应：一例病例报告。
Front Pharmacol. 2023 Jul 26;14:1256801. doi: 10.3389/fphar.2023.1256801. eCollection 2023.
2
Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.病例报告：ROS1融合阳性晚期肺腺癌患者对免疫化疗的持久反应：一例病例报告。
Front Pharmacol. 2022 Sep 9;13:898623. doi: 10.3389/fphar.2022.898623. eCollection 2022.
3
A lung adenocarcinoma patient with fusion and germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of inhibitors: a case report.一名伴有融合和胚系突变的肺腺癌患者在抑制剂治疗失败后，接受信迪利单抗联合尼拉帕利治疗，实现了长期无进展生存：一例报告
Ann Transl Med. 2022 Aug;10(16):912. doi: 10.21037/atm-22-3582.
4
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with -rearranged lung adenocarcinoma.阿来替尼治疗后耐药的伴有-重排肺腺癌患者的免疫化疗短期应答和免疫特征。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001967.
5
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With V600E Mutation: A Case Report.阿替利珠单抗联合铂类化疗对未经治疗的非吸烟V600E突变肺腺癌患者的持久反应：一例报告
Front Oncol. 2021 Jun 10;11:634920. doi: 10.3389/fonc.2021.634920. eCollection 2021.
6
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.一例晚期肺腺癌患者中新型MPRIP-ROS1融合的鉴定及克唑替尼的临床疗效：病例报告
Onco Targets Ther. 2020 Oct 13;13:10387-10391. doi: 10.2147/OTT.S270961. eCollection 2020.
7
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.培美曲塞为基础的化疗在 ROS1 融合阳性肺腺癌患者中的疗效与东亚人群中携带其他驱动基因突变患者的疗效比较。
J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16.
8
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.恩曲替尼治疗 ROS1 融合阳性非小细胞肺癌：三项 1 期-2 期临床试验的汇总分析。
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
9
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.克唑替尼与铂类化疗作为不同 ROS1 融合变异晚期非小细胞肺癌的一线治疗。
Cancer Med. 2020 May;9(10):3328-3336. doi: 10.1002/cam4.2984. Epub 2020 Mar 13.
10
Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with fusion.病例报告：一名晚期非小细胞肺癌伴 融合患者对克唑替尼治疗的反应。
Front Oncol. 2023 Apr 20;13:1169876. doi: 10.3389/fonc.2023.1169876. eCollection 2023.
Zotero 插件